RECRUITINGOBSERVATIONAL
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
A Multi-Centre Prospective Community-Based Observational Study on Prediction of Malignant Progression of Clinically Suspicious Oral Lesions With STRATICYTE
About This Trial
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
Who May Be Eligible (Plain English)
Who May Qualify:
- Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma
Who Should NOT Join This Trial:
- Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma
Exclusion Criteria:
* Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
Treatments Being Tested
PROCEDURE
Standard of Care Histopathology
Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer
PROCEDURE
STRATICYTE Assessment
Assessment for risk of progression to oral cancer
Locations (3)
Kingsway Oral & Maxillofacial Surgery
Edmonton, Alberta, Canada
University of Alberta
Edmonton, Alberta, Canada
Western University
London, Ontario, Canada